Ser56

Site Information
sGsGEREsPERKLLQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 25282834

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	786-O (renal) [VHL (human), transfection] ( 2 ) , 786-O (renal) ( 2 ) , breast ( 1 ) , Jurkat (T lymphocyte) ( 5 ) , liver ( 3 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
3	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
4	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
5	Possemato A (2008) CST Curation Set: 3661; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:pSXXXpS Curated Info